CTOs on the Move

InMed Diagnostics

www.inmedllc.com

 
InMed Diagnostics is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.inmedllc.com
  • 1401 Shop Rd Suite A
    Columbia, SC USA 29201
  • Phone: 803.227.1481

Executives

Name Title Contact Details

Similar Companies

Elixirgen Therapeutics

A clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines

Parexel

PAREXEL International Corporation is the world`s leading innovator of biopharmaceutical services. We simplify our clients` journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world.

Mineralys Therapeutics

At Mineralys Therapeutics we aim to redefine hypertension diagnosis, management and treatment. We are driven to break the “trial and failure” approach to hypertension management and bring a personalized approach to the management of hypertension.

FEI Systems

FEI Systems is a leading IT company specializing in Federal and Local Government data system solutions, and for the past decade we have maintained a leading position in providing programming and consulting services in our primary areas of expertise- Behavioral Health Data Systems, and Clinical Trials Software Solutions for institutional systems of care. At the heart of our success you`ll find a talented team of experts who have helped our customers bridge the gap between the business needs of their organization, and the application of technologies required to successfully manage them.

Volastra Therapeutics

Volastra aims to extend the lives of patients with cancer by leveraging unique insights into chromosomal instability. Moving away from primary tumor models to target the site of metastasis in the toughest-to-treat solid tumors, we are altering the treatment paradigm for metastatic cancers.